Cohance Lifesciences Limited , a global technology-led CDMO and API+ organization, has announced significant changes in its leadership structure. The company's Board of Directors, in a meeting held on October 28, 2025, approved several key decisions that will reshape its top management.

Leadership Transition

Dr. V Prasada Raju has resigned from his position as Managing Director and Director of Cohance Lifesciences. His resignation will take effect from the close of business hours on October 28, 2025. Dr. Raju, in his resignation letter, cited personal priorities and a desire to continue his learning journey as reasons for his departure.

The Board has approved the appointment of Mr. Himanshu Agarwal, the company's current Chief Financial Officer, as an Additional Director. Mr. Agarwal will be designated as Whole-time Director and Chief Financial Officer, effective October 29, 2025, for a five-year term, subject to shareholder approval through a postal ballot process.

Key Details of the Transition

Profile of the New Appointee

Mr. Himanshu Agarwal brings extensive experience to his new role. He is a finance professional with over 30 years of work experience across multiple countries and finance profiles. Mr. Agarwal has been associated with Cohance Lifesciences as CFO since January 2, 2024.

His prior experience includes roles at multinational companies such as ICI India, Huhtamaki, AkzoNobel India, and AstraZeneca Pharma. Notably, Mr. Agarwal has served as CFO and Whole-time Director at some of these organizations.

Revised Key Managerial Personnel

The company has also updated its list of authorized Key Managerial Personnel, which now includes:

1. Mr. Vivek Sharma - Executive Chairman
2. Mr. Himanshu Agarwal - Whole-time Director and CFO
3. Mr. Kundan Kumar Jha - Company Secretary

This leadership transition marks a significant change for Cohance Lifesciences as it continues to evolve in the global pharmaceutical industry.

Cohance Lifesciences Limited , a pharmaceutical company, has received an Official Action Indicated (OAI) classification from the United States Food and Drug Administration (USFDA) for its Finished Dosage Formulations Manufacturing Facility located in Nacharam, Hyderabad.

Key Points

1. USFDA Inspection Outcome:

   • The facility underwent a USFDA inspection
   • Resulted in Form 483 with 6 observations
   • Subsequently classified as Official Action Indicated (OAI)

2. Company's Response:

   • Initiated a comprehensive remediation program
   • Aim: To align the facility with global standards

3. Operational Status:

   • The facility continues normal operations

4. Financial Impact:

   Metric	Contribution
   US Revenue from this unit	< 2.00% of consolidated revenues
   EBITDA Contribution	< 1.00%

5. Company's Outlook:

   • Expects no material impact on ongoing operations or supplies

Analysis

The OAI classification by the USFDA is a significant development for Cohance Lifesciences. It indicates that objectionable conditions were found during the inspection, resulting in Form 483 with multiple observations. However, the company's swift response in initiating a remediation program demonstrates its commitment to addressing these concerns.

From a financial perspective, the limited contribution of this facility to the company's overall revenue and EBITDA suggests that the immediate impact on Cohance Lifesciences' financials may be minimal. This could explain why the company anticipates no material impact on its ongoing operations or supplies.

Investors and stakeholders should monitor the progress of the remediation program and any further communications from the USFDA regarding the facility's status. The company's ability to successfully address the observations and regain full compliance will be crucial for maintaining its position in the US market and ensuring long-term growth prospects.